Thurston Springer Miller Herd & Titak Inc. Boosts Holdings in Danaher Co. (NYSE:DHR)

Thurston Springer Miller Herd & Titak Inc. increased its holdings in Danaher Co. (NYSE:DHR) by 33.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,662 shares of the conglomerate’s stock after purchasing an additional 1,181 shares during the period. Thurston Springer Miller Herd & Titak Inc.’s holdings in Danaher were worth $1,070,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Teachers Insurance & Annuity Association of America purchased a new stake in Danaher during the third quarter valued at about $39,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Danaher in the 3rd quarter valued at about $40,000. FSA Wealth Management LLC purchased a new stake in Danaher during the 3rd quarter valued at about $50,000. Darwin Wealth Management LLC bought a new position in Danaher during the 3rd quarter worth approximately $55,000. Finally, Modus Advisors LLC bought a new stake in Danaher in the fourth quarter valued at approximately $56,000. Institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on DHR. Guggenheim began coverage on shares of Danaher in a report on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price on the stock. Citigroup lowered their price objective on shares of Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a research note on Monday, January 6th. TD Cowen raised their target price on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. KeyCorp increased their price objective on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Finally, Robert W. Baird reduced their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Trading Down 1.0 %

Shares of NYSE DHR opened at $237.58 on Wednesday. The stock has a market cap of $171.60 billion, a P/E ratio of 45.34, a price-to-earnings-growth ratio of 4.32 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 1 year low of $222.53 and a 1 year high of $281.70. The firm has a 50-day moving average of $235.27 and a 200 day moving average of $253.56.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the firm posted $2.02 EPS. The business’s revenue for the quarter was up 3.1% compared to the same quarter last year. As a group, sell-side analysts expect that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio is presently 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.